For Industry

What is the best end-point in clinical trials of drugs for cancer?

Our method is capable of detecting one cancer cell among 10.000-1.000.000 cells with a higher specificity than standard methods (Flow Cytometry). Our method has high applicability >95% for Myeloma and >85% in acute myeloid leukemia.

Our method has been validated in clinical studies in multiple myeloma and acute myeloid leukemia where MRD by NGS for this method is associated with Overall Survival. At present, MRD tracking has been correlated with clinical outcome in chronic lymphoid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, and is under study in other solid tumor diseases.

This methodology is employed as an end-point in clinical trials as a biomarker of response.

Our products

products in different stages of development
MRDeep

Genetic In vitro test to detect and quantify residuals cancer cells in hematological tumors. SNV, Indels or Ig rearrangements detected at baseline point are used as tumor biomarker in follow-up bone marrow samples.

MRSolid

Genetic In vitro test to detect and quantify residuals cancer cells in solid tumors. Peripheral blood sample is used as a source of tumor DNA, cell free DNA or CTC, commonly named as liquid biopsy.
SNV and Indels are used as tumor biomarkers and are monitored in follow-up blood samples.

ClonEv

Genetic In Vitro test to characterize changes in tumor clonality and detect the emergency of important mutations for drug efficacy.
SNV and Indels are used as tumor biomarkers and are monitored in follow-up blood samples.